Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-910 multiple-dose PK and safety by CYP2C19 genotype in healthy Japanese males
jRCT2071250002Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KP-910, sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of KP-910 and Safety and tolerability of KP-910. Started Apr 2025; status: completed.
02
Drugs
KP-910
Beyond the preview
Go deeper on jRCT2071250002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250002.